The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First disclosure of frontline treatment (1L tx) with the selective CDK4 inhibitor BGB-43395 in combination with letrozole for metastatic HR+/HER2- breast cancer (BC): A phase 1 safety expansion.
 
Shom Goel
Consulting or Advisory Role - Belharra Therapeutics; BeOne Medicines; Halda Therapeutics; Incyclix Bio; Lilly; Pfizer
Research Funding - Lilly
 
Laura Testa
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Novartis
Speakers' Bureau - BeOne; Daiichi Sankyo/Astra Zeneca; Lilly; Menarini; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; MSD Oncology; Roche
 
Fernanda Damian
No Relationships to Disclose
 
Pei Jye Voon
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Johnson & Johnson/Janssen; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer
Speakers' Bureau - Amgen; AstraZeneca; Johnson & Johnson/Janssen; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Johnson & Johnson/Janssen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Revolution Medicines (Inst); ROCHE (Inst); Viracta Therapeutics (Inst)
 
Daniele Suzuki
Consulting or Advisory Role - Daiichi Sankyo/Lilly
Travel, Accommodations, Expenses - AstraZeneca
 
Roberto Hegg
No Relationships to Disclose
 
Dayana Ribeiro
No Relationships to Disclose
 
Heloisa Rodrigues
Travel, Accommodations, Expenses - Pfizer
 
Jose Bines
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Knight Pharmaceuticals; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Roche
 
Iurie Bulat
No Relationships to Disclose
 
Hua-Xin Gao
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Surendra Chaudhary
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Patrick Schnell
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Ting Deng
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Hao Zheng
Employment - BeOne Medicines
Stock and Other Ownership Interests - Alnylam; BeOne Medicines; Revolution Medicines
 
Timothy Yap
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Blueprint Medicines; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; ProLynx; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics; Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); Department of Defense; EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); NIH/NCI; Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tango Therapeutics; Tesaro (Inst); V Foundation; Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)